Sanofi (SAN) | Within Fair Value — October 2026
All the numbers presented in the article are taken directly from our dashboards.
Sanofi (SAN) is a Paris-headquartered global healthcare enterprise dedicated to research, development, manufacturing, and commercialization of therapeutic solutions across Europe, the United States, and other international markets. Its business operations are structured into three primary divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare.
The Pharmaceuticals segment delivers specialized treatments, encompassing human monoclonal antibodies and therapies for a range of conditions such as multiple sclerosis, neurological disorders, various inflammatory and immunological diseases, rare disorders, oncology, and rare blood conditions. This division also provides medications for diabetes, cardiovascular health, and a portfolio of established prescription drugs.
Through its Vaccines division, Sanofi supplies crucial immunizations, including pediatric vaccines for diseases like poliomyelitis, pertussis, and Hib, alongside adult vaccines addressing influenza, booster needs, meningitis, and those required for travel or endemic regions.
The Consumer Healthcare portfolio features over-the-counter remedies for common ailments such as allergies, coughs and colds, and pain relief. It also includes products for liver care, general physical and mental wellness, probiotics, digestive health, and nutritional support. Additionally, this segment offers personal care items like daily body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and powders for eczema. Sanofi maintains an active pipeline with numerous pharmaceutical products and vaccines currently undergoing various stages of development.
Operations
Full-Year 2025
Revenue +21% YoY.
EBITDA +31% YoY.
Net sales +7% YoY.
Free cash flow €8.09B, +35.8% YoY
Officially closed the sale of a 50% controlling stake in its former Consumer Healthcare division to private equity firm CD&R, rebranding it as Opella Healthcare Group—retaining a 48.2% stake in the new company.
Completed an asset-specific acquisition of the drug DR-0201 from Dren Bio, Inc. in May.
Acquired Blueprint Medicines, a global biopharmaceutical company, and private British vaccine developer Vicebio Ltd. in July.
Acquired Vigil Neuroscience in August.
Q1 2026
Net sales +6.2%.
Business net income +2.4% (IRFS income -13.8%).
Free cash flow +2.4%.
Five regulatory approvals in immunology.
Two regulatory submission acceptances.
Completed the acquisition of Dynavax Technologies Corporation in February.
Completed €921M of their €1B share buyback program.
Q2 2026
Net sales +16%.
Business net income +28.9% (IRFS income -91.3%).
Free cash flow +86.8%.
Seven regulatory approvals in immunology, rare diseases, oncology, and neurology.
Four regulatory submission acceptances.
Full completion of their €1B share buyback program.
Updated guidance, with sales expected to rise 10% (at CER).
Recently—as of October—the European Commission officially accepted a legally binding settlement from Sanofi to close its antitrust investigation into whether the company used its dominant market position in France and Germany to run a "misleading communication campaign". Regulators had alleged that between the periods of 2024 and late 2025, Sanofi’s marketing materials unfairly disparaged Fluad—a competing elderly flu vaccine manufactured by CSL Seqirus—by portraying it as scientifically inferior and subject to medical objections.
The company successfully avoided a catastrophic headline risk and a statutory fine of up to 10% of its global annual turnover, with the agreement legally requiring Sanofi to strip any negative framing from its promotional materials and actively publish online clarifications stating that national health guidelines treat both enhanced vaccines as clinically equivalent—valid until March 2030
Valuation
Key Takeaways
Elevated earnings per share growth. ✔️
Concentrated market dominance within its respective fields (vaccines and immunology). ✔️
Aggressive free cash flow generation. ✔️
At the time of writing, the company is essentially right on top of its fair value according to our proprietary estimate.
Risks
Negative average price performance over the projected period. ❌
A considerable percentage of the company’s total valuation is tied to its flagship immunology asset, Dupixent. ❌
Pipeline execution risk. ❌
Sustained Performance & Conclusion
Variables include:
Efficient commercialization of its recently acquired assets. ⚠️
Sustain of high-margin biopharma growth following the structural spin-off of its former Consumer Healthcare unit. ⚠️
Sanofi’s valuation in the long-term is dependent upon management's ability to shift its newly streamlined operational structure into compounding returns. By transitioning into a pure-play innovative medicine entity and recycling capital into high-yield biotech buyouts, the company has built up its core revenue lines against retail drags. Ultimately, the equity represents a balanced, low-volatility asset trading effectively at where fundamental numbers say it should be.
Best regards,
- The Intrival Team
